| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 5,664.72 | 3,624.6 | 4,400.71 | 3,462.88 | 2,633.24 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 5,664.72 | 3,624.6 | 4,400.71 | 3,462.88 | 2,633.24 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 170.24 | 240.46 | 223.94 | 134.78 | 139.17 |
Total Income | 5,834.96 | 3,865.06 | 4,624.65 | 3,597.65 | 2,772.41 |
Total Expenditure | 4,331.65 | 2,656.3 | 2,890.56 | 2,160.65 | 1,677.77 |
PBIDT | 1,503.31 | 1,208.77 | 1,734.09 | 1,437 | 1,094.64 |
Interest | 26.2 | 7.45 | 5.24 | 3.41 | 7.18 |
PBDT | 1,477.11 | 1,201.32 | 1,728.85 | 1,433.59 | 1,087.45 |
Depreciation | 344.57 | 146.74 | 110.3 | 98.78 | 94.59 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 345.75 | 276.34 | 392.88 | 337.73 | 251.83 |
Deferred Tax | 14.33 | -2.8 | 14.01 | 0.12 | -31.82 |
Reported Profit After Tax | 772.46 | 781.04 | 1,211.66 | 996.96 | 772.86 |
Minority Interest After NP | 0 | 0 | 0 | 0 | 0 |
Net Profit after Minority Interest | 772.46 | 781.04 | 1,211.66 | 996.96 | 772.86 |
Extra-ordinary Items | 0 | -41.67 | 0 | 0 | 0 |
Adjusted Profit After Extra-ordinary item | 772.46 | 822.71 | 1,211.66 | 996.96 | 772.86 |
EPS (Unit Curr.) | 46.9 | 47.44 | 73.81 | 63.07 | 49.88 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 2,000 | 0 | 0 | 0 | 0 |
Equity | 16.47 | 16.47 | 16.43 | 16.36 | 15.5 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 26.53 | 33.34 | 39.4 | 41.49 | 41.57 |
PBDTM(%) | 26.07 | 33.14 | 39.28 | 41.39 | 41.29 |
PATM(%) | 13.63 | 21.54 | 27.53 | 28.78 | 29.35 |
The FDA conducted the pre-approval inspection (PAI) from Feb. 19, 2025, to Feb. 25, 2025, as part of the regulatory process for sterile APIs.
Here are some of the stocks that may see significant price movement today: Tata Chemicals, Power Grid, Welspun Enterprises, etc.
EBITDA (Earnings Before Interest, Tax, Depreciation, and Amortization) increased by 1% YoY to ₹360 crore, compared to ₹356.4 crore in the previous year.
Sintilimab is marketed in China as TYVYT (sintilimab injectable) and was co-developed by Innovent and Eli Lilly.
Here are some of the stocks that may see significant price movement today: Power Mech, IndiGo, NHPC, Gland Pharma, etc.
Gland Pharma stock has gained a total of 12% in the last one year, and 7.37% dip since the beginning of the year.
Here are some of the stocks that may see significant price movement today: Tata Power, Chambal Fertilisers, Cummins India, etc.
The inspection concluded with three 483 observations. Gland Pharma clarified that these observations are procedural and not related to data integrity or repeat issues.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
